新辅助同步放化疗治疗局部晚期低位直肠癌的疗效观察  

作　　者：王耀辉[1] 贾海艳[1] 秦英[1] 

机构地区：[1]四平市中心医院,136000

出　　处：《当代医学》2009年第36期57-58,共2页Contemporary Medicine

摘　　要：目的探讨新辅助同步放化疗治疗局部晚期低位直肠癌的疗效及安全性。方法42例局部晚期(T3～4N0～1M0)低位直肠癌患者术前接受同步放化疗,术前放疗总剂量46Gy,同步行口服卡培他滨化疗。放化疗后4～6周行手术治疗,术式选择依据患者情况而定。结果全部患者均完成治疗。Ⅰ、Ⅱ级毒性反应总发生率为72.0%,Ⅲ、Ⅳ级为28.0%。同步放化疗后T分期下降率38.1%,N分期下降率为38.1%。保肛率为45.2%。手术并发症发生率为20%。结论新辅助同步放化疗治疗局部晚期低位直肠癌安全有效,降低肿瘤分期、提高保肛率的同时改善了患者的生存质量。Objective To explore the safety and efficacy of neoadjuvant concurrent chemoradiotherapy on locally advanced low rectal cancer.Methods 42 cases with locally advanced low rectal cancer（T3-4N0-1M0） underwent preoperative radiochemo-therapy.Capecitabine was orally administered concurrently with radiotherapy（total dose 46 Gy）.Surgery was performed 4-6 weeks after completion of chemo-radiotherapy,surgical were chosen appropriately according to patients＇ situation.Results All the patients completed the planned treatment.The rate of grade 1,2 acute toxicity was 72.0% and grade 3,4 was 28%.38.1% patients had a T downstaging and 38.1% patients had a N dowstaging.The sphincter preservation rate was45.2%.Complications after operation was 20.0%.Conclusion Neoadjuvant concurent chemoradiotherapy is feasible and effective.It improves clinical stage,sphincter preservation and the quality of life in patients with locally advanced low rectal cancer.

关 键 词：直肠肿瘤 辅助治疗 同步放化疗 

分 类 号：R735.37[医药卫生—肿瘤]